Corridor Pharmaceuticals, Inc.

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors. Dr. Strobeck has more than 20 years of experience in operations, business development, capital raising and M&A and has a track record of success creating and building value for emerging and public biotechnology and life sciences companies. Currently, Dr. Strobeck is President and CEO, and a Member of the Board, at Rockwell Medical, a publicly held healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Prior to joining Rockwell in 2022, Dr. Strobeck was a Managing Partner at Aquilo Partners, a life science investment banking firm specializing in M&A and strategic partnering transactions. Additionally, he was COO at Zyla Lifesciences (acquired by Assertio Therapeutics), President and CEO of Corridor Pharmaceuticals (acquired by AstraZeneca), and CBO of Topaz Pharmaceuticals (acquired by Sanofi Pasteur). Dr. Strobeck also served as CBO of Trevena, and Vice President of Business Development at GSK where he was responsible for numerous transactions. Earlier in his career, he worked at two venture capital firms, SR One and EuclidSR Partners making investments in drug discovery and drug development companies. Dr. Strobeck completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania, earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, and earned his bachelor's degree in biology from St. Lawrence University. Craig Fraser, Windtree's President and Chief Executive Officer said, “We are pleased to welcome Mark as a new independent director to Windtree's Board of Directors. Mark's R&D background, combined with his broad professional and deal experience, will be invaluable for Windtree as we work to advance our clinical development programs and pursue transactions that will potentially drive value for our shareholders. Mark will be highly complementary to our existing Board of Directors which includes Dan Geffkin, Leslie Williams, Dr. Rob Scott and myself, as we continue to advance therapies to treat critically-ill cardiac patients.” "I am excited to join Craig and the Windtree team and support their strategy and vision going forward," said Dr. Strobeck. "There is a significant unmet medical need in the cardiovascular space, and I am excited by istaroxime's unique mechanism of action and pharmacological profile. Windtree's portfolio has the potential to significantly benefit patients suffering from cardiovascular disease. The Company has a number of strategic opportunities and clinical milestones ahead and I look forward to supporting Windtree to help drive value for patients and shareholders." About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is advancing multiple late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds that have an ability to activate SERCA2a. The Company's lead candidate is istaroxime, a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform also includes follow-on oral pre-clinical SERCA2a activator assets. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s Pharmaceutical (HK) Ltd. Windtree’s portfolio also includes rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the Company’s expectations with respect to market conditions, the timing and completion of the Offering and the intended use of net proceeds from the Offering. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, but are not limited to: risks and uncertainties associated with the economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company’s clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates; the Company’s ability to secure significant additional capital as and when needed; and the Company’s ability to access the debt or equity markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Monique KosseLifeSci Advisors212.915.3820 or monique@lifesciadvisors.com

FlyPharma Conferences are pleased to announce an exciting new addition to its event portfolio: FlyPharma Middle East. Taking place in Abu Dhabi from 20-22 March 2023, FlyPharma Middle East will bring together a global audience of biopharma logistics professionals to discuss the latest supply chain challenges and propose new industry collaborations. The new event will be supported by the Department of Culture and Tourism – Abu Dhabi (DCT Abu Dhabi), the Department of Health – Abu Dhabi and Etihad Cargo. The UAE has a rapidly growing domestic pharmaceutical manufacturing industry, with big pharma and smaller biopharma and biotech companies alike looking to the region’s strategic position between Europe, Asia and Africa to establish a strong industry presence. Alongside this, an efficient and innovative logistics infrastructure offers excellent cargo transport in and out of the region. The UAE’s national airline, Etihad Cargo, offers specially designed, temperature-controlled equipment, shipping pharmaceuticals in the quickest possible time and adhering to the highest compliance guidelines. Abu Dhabi was chosen as the latest location for FlyPharma because of its reputation as a dynamic business destination, built on its strategic regional location, fast-growing knowledge economy and innovative healthcare ecosystem. Even more importantly, the HOPE Consortium – a complete supply chain solution, developed by Abu Dhabi to facilitate availability of COVID-19 vaccines worldwide – demonstrated the Emirate’s commitment to the global battle against the pandemic. Combining its unique logistical capabilities with its geographical proximity to around 4.5 billion people worldwide, Abu Dhabi has led one of the largest and most integrated pharma logistics efforts of its type, which has successfully delivered over 260 million vaccine doses to the global community. The Emirate’s focus on pharma logistics and its commitment to driving change makes the region the perfect location to host the next FlyPharma conference. Tailored to an audience of forward-thinking pharma and cargo decision-makers, the event will deliver a platform for dynamic and lively dialogue between speakers and delegates, and will consider themes such as vaccine distribution challenges, smart supply chains, remote and emergency logistics solutions, sustainability, collaboration opportunities and more. This will be the ninth FlyPharma conference to take place since its inaugural event in 2015 and the first to take place in the Middle East. In addition to leveraging Abu Dhabi’s strong MICE tourism infrastructure and capabilities, the organiser of FlyPharma Middle East, Samedan Ltd, has also received additional support from the Abu Dhabi Convention and Exhibition Bureau (ADCEB) through the ‘Advantage Abu Dhabi 2.0’ programme. As part of the DCT Abu Dhabi, ADCEB utilises this enhanced subvention scheme to empower event organisers with an array of support throughout the event planning cycle, including financial assistance and destination-driven value-adds. Mubarak Al Shamisi, the Director of ADCEB at DCT Abu Dhabi, said: “We are proud to collaborate with the Department of Health – Abu Dhabi Etihad Cargo, and the HOPE Consortium to geo-clone the prestigious FlyPharma conference for its Middle East debut. To host the gathering of (bio)pharma logistics professionals in Abu Dhabi for the first-ever FlyPharma Middle East is a remarkable milestone in our ever-expanding business events calendar. Conferences such as FlyPharma are not only a testament to Abu Dhabi as a highly competitive destination for strategic business events, but they also highlight the growing knowledge ecosystem of the emirate. We look forward to welcoming delegates next year and invite them to explore the destination at their own pace and discover the diverse range of exciting, inspiring and restoring experiences found in Abu Dhabi.” Martin Drew, Senior Vice President Global Sales & Cargo at Etihad Aviation Group, said: “As a founding member of the HOPE Consortium, Etihad Cargo is proud to participate in the inaugural FlyPharma Middle East conference. In full alignment with Abu Dhabi’s vision of becoming a global hub for pharmaceuticals and life sciences, Etihad Cargo has expanded its International Air Transport Association (IATA) Center of Excellence for Independent Validators (CEIV) Pharma certified PharmaLife product, which has enabled the carrier to triple pharmaceutical volumes shipped in less than two years. FlyPharma Middle East provides the perfect platform for Etihad Cargo to share insights into its multi-phased pharmaceutical cargo infrastructure development strategy, including the launch of Pharma Corridor 2.0 between Abu Dhabi and Brussels in partnership with the HOPE Consortium, Abu Dhabi Airports Company (ADAC), Brussels Airport Company and Pharma.Aero, and the expansion of the carrier’s state-of-the-art pharma facility, which is the latest step in Etihad Cargo’s continued commitment to develop a Cool Chain Centre of Excellence at its UAE hub.” FlyPharma Middle East’s Conference Director, Angela Heath, commented: “It is always exciting to launch a new conference, but I am particularly looking forward to presenting FlyPharma Middle East to new and regular delegates. The opportunity to facilitate meaningful conversations between pharma and cargo decision-makers, and make a genuine difference to the future of the industry, is key with FlyPharma conferences and Abu Dhabi offers an ideal location to bring a global representation of multiple supply chain stakeholders into one room. I am looking forward to collaborating with our new sponsors and partners to build on the success of our recent FlyPharma Conference Europe, held in Leipzig in September 2022, and tap into their experience and ideas to build a very strong event programme.” This new FlyPharma conference in Abu Dhabi will expand from two days to three and is expected to feature an exclusive site tour of Abu Dhabi International Airport, including Etihad Cargo’s dedicated temperature-controlled facilities and two evening networking events, including a gala dinner. The team at FlyPharma Middle East 2023 is looking forward to welcoming delegates to Abu Dhabi from 20-22 March. Registration will open on Monday 19 December 2022. To join your industry colleagues to learn, connect and network with the pharma supply chain’s brightest minds, email Simon Caplan at simon@samedanltd.com . Visit www.FlyPharmaMiddleEast.com from 19 December to find out more about the event or email kayleigh@samedanltd.com with any delegate or agenda enquiries. About the Department of Culture and Tourism – Abu Dhabi: The Department of Culture and Tourism – Abu Dhabi (DCT Abu Dhabi) drives the sustainable growth of Abu Dhabi’s culture and tourism sectors, fuels economic progress and helps achieve Abu Dhabi’s wider global ambitions. By working in partnership with the organisations that define the Emirate’s position as a leading international destination, DCT Abu Dhabi strives to unite the ecosystem around a shared vision of the Emirate’s potential, coordinate effort and investment, deliver innovative solutions and use the best tools, policies, and systems to support the culture and tourism industries. DCT Abu Dhabi’s vision is defined by the Emirate’s people, heritage and landscape. We work to enhance Abu Dhabi’s status as a place of authenticity, innovation and unparalleled experiences, represented by its living traditions of hospitality, pioneering initiatives and creative thought. For more information about DCT Abu Dhabi and the destination, visit tcaabudhabi.ae and visitabudhabi.ae . For Abu Dhabi Calendar, please visit inabudhabi.ae . About the Department of Health – Abu Dhabi: The Department of Health – Abu Dhabi (DOH) is the regulatory body of the Healthcare Sector at the Emirate of Abu Dhabi and ensures excellence in healthcare for the community by monitoring the health status of the population. DOH defines the strategy for the health system and monitors and analyses the health status of the population and the performance of the system. In addition, DOH shapes the regulatory framework for the health system, inspects for regulations, enforces standards and encourages the adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DOH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi, in addition to regulating scope of services, premiums and reimbursement rates of the health system in the Emirate of Abu Dhabi. For more information visit www.doh.gov.ae . About Etihad Cargo: Etihad Cargo is the cargo and logistics arm of the Etihad Aviation Group. Since its establishment in 2004, Etihad Cargo has grown rapidly to become one of the leading air cargo carriers in the world, offering customers a range of cargo products and services for five major continents. Its hub in Abu Dhabi is strategically located at the centre of the world's busiest trade lanes, providing an integral link between Asia, Europe, North America, Australia and Africa. In addition to general cargo, Etihad Cargo offers a wide range of specialty products including live animals, dangerous goods, valuables and vulnerables and personal effects, as well as its market-leading cold chain products (the latter holding IATA's stringent Centre of Excellence for Independent Validators certifications for both Pharmaceutical and Perishables Logistics, as well as Live Animals Logistics). For more information, please visit www.etihadcargo.com . About FlyPharma Conferences, Samedan Ltd and PMGroup Worldwide Ltd: FlyPharma Conferences are aimed at forward-thinking individuals and businesses that are ready to uncover the potential of their pharma supply chains. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology and how to encourage collaboration between supply chain players. FlyPharma Conferences are run by specialist pharmaceutical publisher Samedan Ltd, producing a range of market-leading magazines for senior and middle-management professionals across the global pharma and life sciences sectors. In 2021, Samedan Ltd became part of PMGroup Worldwide Ltd and Datateam Media Group. The acquisition brings together three publishing powerhouses in the pharmaceutical and healthcare sector. As well as joining forces with established titles like PME, PharmaTimes and digital products PMLiVE and pharmatimes.com, PMGroup runs a number of awards programmes that recognise best practice in the pharma and healthcare sectors. The union has allowed all brands to expand their readership and their live, virtual and hybrid events and award schemes. Press contact Information: Kayleigh Smith, Conference and Events Executive, email: kayleigh@samedanltd.com Angela Heath, Conference Director, email: angela@samedanltd.com